Search Results

JAMA Publishes GRAVITAS

March 16, 2011—Matthew J. Price, MD, et al have published results of the GRAVITAS (Gauging Responsiveness With a VerifyNow Assay—Impact on Thrombosis and Safety) study in the Journal of the American Medical Association (2011;305:1097–1105). The study sought to evaluate the impact of high-dose compared with standard-dose clopidogrel (Plavix, Bristol- Myers Squibb/Sanofi Pharmaceuticals Partnership, New York, NY) on patients with high on-treatment platelet reactivity after percutaneous coronary intervention (PCI).

GRAVITAS Trial Published in JAMA

March 16, 2011— Matthew J. Price, MD, et al have published results of the GRAVITAS (Gauging Responsiveness With a VerifyNow Assay—Impact on Thrombosis and Safety) study in the Journal of the American Medical Association (2011;305:1097–1105).

Watchman LAA Closure Compared With Long-Term Warfarin Regarding Bleeding Outcomes

November 25, 2015—A comparison of the relative risk of major bleeding in left atrial appendage closure (LAAC) compared with long-term warfarin therapy was published online ahead of print by Matthew J. Price, MD, et al in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

Clinical Study of Medtronic's Resolute Onyx 2.0-mm DES for Extra Small Vessels Meets Primary Endpoint

May 18, 2017—Medtronic announced that the Resolute Onyx 2.0-mm drug-eluting stent (DES) met its primary endpoint of target lesion failure (TLF) at 1 year for the treatment of coronary artery disease in extra-small vessels.

Medtronic Begins Bifurcation Cohort of the RESOLUTE ONYX Postapproval Study

May 18, 2018—Medtronic announced the initiation of a clinical study in the United States to assess the safety and efficacy of drug-eluting stents (DESs) for the treatment of bifurcation lesions.

Boston Scientific’s Watchman Associated With Low Rate of Stroke in NCDR LAAO Registry

May 15, 2021—Transcatheter left atrial appendage occlusion (LAAO) with the Watchman device (Boston Scientific) was associated with a low rate of stroke at 1 year even among older patients with atrial fibrillation (AFib) who faced a high risk for stroke or bleeding based on their previous health history.

Medtronic's Resolute Onyx 2.0-mm DES Approved and Launched in the United States

February 26, 2018—Medtronic announced US Food and Drug Administration (FDA) approval and the United States launch of the company's Resolute Onyx 2.0-mm drug-eluting stent (DES), which is specifically designed to treat small vessels.

GRAVITAS Finds High Dose of Clopidogrel Is No Better Than Standard Dose for High-Risk DES Patients

November 16, 2010—Compared to the standard dose, a high dose of clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, New York, NY) did not reduce the incidence of death, myocardial infarction, and in-stent restenosis in certain high-risk patients who had drug-eluting stents implanted, according to late-breaking clinical trial results reported at the American Heart Association's (AHA) Scientific Sessions 2010.

St. Jude Medical Announces FDA Approval and Launch of Ilumien Optis System

October 22, 2013—St.